Lumacaftor/ivacaftor in Cystic Fibrosis: Effects on Glucose Metabolism and Insulin Secretion

Overview

Journal J Endocrinol Invest

Publisher Springer

Specialty Endocrinology

Date 2021 Feb 15

PMID 33586024

Citations 14

Authors

C Colombo

A Foppiani

A Bisogno

S Gambazza

V Dacco

E Nazzari

A Leone

A Giana

A Mari

A Battezzati

Affiliations

Soon will be listed here.

Abstract

Purpose: The question whether the new cystic fibrosis transmembrane conductance regulator (CFTR) modulator drugs aimed at restoring CFTR protein function might improve glucose metabolism is gaining attention, but data on the effect of lumacaftor/ivacaftor treatment (LUMA/IVA) on glucose tolerance are limited. We evaluated the variation in glucose metabolism and insulin secretion in CF patients homozygous for Phe508del CFTR mutation after one-year treatment with LUMA/IVA in comparison to patients with the same genotype who did not receive such treatment.

Methods: We performed a retrospective case-control study on 13 patients with a confirmed diagnosis of CF, homozygous for the Phe508del CFTR mutation, who received LUMA/IVA for one year (cases) and 13 patients with identical genotype who did not receive this treatment (controls). At the beginning and conclusion of the follow-up, all subjects received a modified 3 h OGTT, sampling at baseline, and at 30 min intervals for plasma glucose, serum insulin, and c-peptide concentrations to evaluate glucose tolerance, and quantify by modeling beta-cell insulin secretion responsiveness to glucose, insulin clearance and insulin sensitivity.

Results: LUMA/IVA did not produce differences in glucose tolerance, insulin secretory parameters, clearance and sensitivity with respect to matched controls over one-year follow-up.

Conclusion: We found no evidence of improvements in glucose tolerance mechanisms in patients with CF after one-year treatment with LUMA/IVA.

Citing Articles

Low-added sugar dietary intervention study to mitigate glucose intolerance and improve body composition in adults with cystic fibrosis: a protocol of a double-blind, randomised study.

Zaveri S, Stecenko A, Hunt W, Goss A, Sharma P, Hartman T BMJ Open. 2024; 14(12):e092503.

PMID: 39725418 PMC: 11683900. DOI: 10.1136/bmjopen-2024-092503.

One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational Study.

Bassi M, Strati M, Spiandorello G, Scalas M, Cresta F, Calevo M Life (Basel). 2024; 14(10).

PMID: 39459609 PMC: 11509452. DOI: 10.3390/life14101309.

An experimentally validated approach to automated biological evidence generation in drug discovery using knowledge graphs.

Sudhahar S, Ozer B, Chang J, Chadwick W, ODonovan D, Campbell A Nat Commun. 2024; 15(1):5703.

PMID: 38977662 PMC: 11231212. DOI: 10.1038/s41467-024-50024-6.

An Update in Cystic Fibrosis-Related Diabetes in Children and Adolescents.

Anton-Paduraru D, Murgu A, Donos M, Trofin F, Azoicai A, Popovici P Children (Basel). 2023; 10(12).

PMID: 38136081 PMC: 10741586. DOI: 10.3390/children10121879.

Oxidative Stress Biomarkers in Cystic Fibrosis and Cystic Fibrosis-Related Diabetes in Children: A Literature Review.

Pinzaru A, Mihai C, Chisnoiu T, Pantazi A, Lupu V, Kassim M Biomedicines. 2023; 11(10).

PMID: 37893045 PMC: 10604378. DOI: 10.3390/biomedicines11102671.

References

Manderson Koivula F, McClenaghan N, Harper A, Kelly C . Islet-intrinsic effects of CFTR mutation. Diabetologia. 2016; 59(7):1350-1355. PMC: 4901107. DOI: 10.1007/s00125-016-3936-1. View

Hayes Jr D, McCoy K, Sheikh S . Resolution of cystic fibrosis-related diabetes with ivacaftor therapy. Am J Respir Crit Care Med. 2014; 190(5):590-1. DOI: 10.1164/rccm.201405-0882LE. View

Misgault B, Chatron E, Reynaud Q, Touzet S, Abely M, Melly L . Effect of one-year lumacaftor-ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients. J Cyst Fibros. 2020; 19(5):712-716. DOI: 10.1016/j.jcf.2020.03.002. View

Colombo C, Alicandro G, Gambazza S, Mileto P, Mari A, Grespan E . Ventilation inhomogeneity is associated with OGTT-derived insulin secretory defects in cystic fibrosis. Pediatr Pulmonol. 2018; 54(2):141-149. DOI: 10.1002/ppul.24212. View

Heijerman H, McKone E, Downey D, Van Braeckel E, Rowe S, Tullis E . Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019; 394(10212):1940-1948. PMC: 7571408. DOI: 10.1016/S0140-6736(19)32597-8. View

Bell S, Mall M, Gutierrez H, Macek M, Madge S, Davies J . The future of cystic fibrosis care: a global perspective. Lancet Respir Med. 2019; 8(1):65-124. PMC: 8862661. DOI: 10.1016/S2213-2600(19)30337-6. View

Li A, Vigers T, Pyle L, Zemanick E, Nadeau K, Sagel S . Continuous glucose monitoring in youth with cystic fibrosis treated with lumacaftor-ivacaftor. J Cyst Fibros. 2018; 18(1):144-149. PMC: 6342629. DOI: 10.1016/j.jcf.2018.07.010. View

Thomassen J, Mueller M, Alejandre Alcazar M, Rietschel E, van Koningsbruggen-Rietschel S . Effect of Lumacaftor/Ivacaftor on glucose metabolism and insulin secretion in Phe508del homozygous cystic fibrosis patients. J Cyst Fibros. 2017; 17(2):271-275. DOI: 10.1016/j.jcf.2017.11.016. View

Volkova N, Moy K, Evans J, Campbell D, Tian S, Simard C . Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries. J Cyst Fibros. 2019; 19(1):68-79. DOI: 10.1016/j.jcf.2019.05.015. View

10.

Moran A, Pillay K, Becker D, Granados A, Hameed S, Acerini C . ISPAD Clinical Practice Consensus Guidelines 2018: Management of cystic fibrosis-related diabetes in children and adolescents. Pediatr Diabetes. 2018; 19 Suppl 27:64-74. DOI: 10.1111/pedi.12732. View

11.

Middleton P, Mall M, Drevinek P, Lands L, McKone E, Polineni D . Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl J Med. 2019; 381(19):1809-1819. PMC: 7282384. DOI: 10.1056/NEJMoa1908639. View

12.

Battezzati A, Bedogni G, Zazzeron L, Mari A, Battezzati P, Alicandro G . Age- and Sex-Dependent Distribution of OGTT-Related Variables in a Population of Cystic Fibrosis Patients. J Clin Endocrinol Metab. 2015; 100(8):2963-71. DOI: 10.1210/jc.2015-1512. View

13.

Wainwright C, Elborn J, Ramsey B, Marigowda G, Huang X, Cipolli M . Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med. 2015; 373(3):220-31. PMC: 4764353. DOI: 10.1056/NEJMoa1409547. View

14.

Boyle M, Bell S, Konstan M, McColley S, Rowe S, Rietschel E . A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med. 2014; 2(7):527-38. DOI: 10.1016/S2213-2600(14)70132-8. View

15.

Bessonova L, Volkova N, Higgins M, Bengtsson L, Tian S, Simard C . Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor. Thorax. 2018; 73(8):731-740. PMC: 6204955. DOI: 10.1136/thoraxjnl-2017-210394. View

16.

Battezzati A, Mari A, Zazzeron L, Alicandro G, Claut L, Battezzati P . Identification of insulin secretory defects and insulin resistance during oral glucose tolerance test in a cohort of cystic fibrosis patients. Eur J Endocrinol. 2011; 165(1):69-76. DOI: 10.1530/EJE-10-1003. View

17.

Bellin M, Laguna T, Leschyshyn J, Regelmann W, Dunitz J, Billings J . Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study. Pediatr Diabetes. 2013; 14(6):417-21. PMC: 3804832. DOI: 10.1111/pedi.12026. View

18.

Ballmann M, Prinz N, Glass A, Holl R . Comment on "Effect of one-year lumacaftor-ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients". J Cyst Fibros. 2020; 19(5):839. DOI: 10.1016/j.jcf.2020.04.009. View

19.

Nguyen T, Collins G, Spence J, Daures J, Devereaux P, Landais P . Double-adjustment in propensity score matching analysis: choosing a threshold for considering residual imbalance. BMC Med Res Methodol. 2017; 17(1):78. PMC: 5408373. DOI: 10.1186/s12874-017-0338-0. View

20.

Mari A, Tura A, Gastaldelli A, Ferrannini E . Assessing insulin secretion by modeling in multiple-meal tests: role of potentiation. Diabetes. 2002; 51 Suppl 1:S221-6. DOI: 10.2337/diabetes.51.2007.s221. View